UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit
Beginning Balance at Dec. 31, 2022	$ (32,314)	$ 3	$ 99,875		$ (132,192)
Beginning Balance (in shares) at Dec. 31, 2022		27,079,856
Exercise of stock options	20		20
Exercise of stock options, (in shares)		15,376
Issuance of Legacy Allurion convertible preferred stock for the exercise of warrants	29		29
Issuance of Legacy Allurion convertible preferred stock for the exercise of warrants (in shares)		3,554
Stock-based compensation expense	409		409
Net Income (Loss)	(17,801)				(17,801)
Ending Balance at Mar. 31, 2023	(49,657)	$ 3	100,333		(149,993)
Ending Balance (in shares) at Mar. 31, 2023		27,098,786
Beginning Balance at Dec. 31, 2022	(32,314)	$ 3	99,875		(132,192)
Beginning Balance (in shares) at Dec. 31, 2022		27,079,856
Net Income (Loss)	(39,797)
Ending Balance at Jun. 30, 2023	(71,218)	$ 3	100,768		(171,989)
Ending Balance (in shares) at Jun. 30, 2023		27,126,904
Beginning Balance at Mar. 31, 2023	(49,657)	$ 3	100,333		(149,993)
Beginning Balance (in shares) at Mar. 31, 2023		27,098,786
Exercise of stock options	28		28
Exercise of stock options, (in shares)		27,626
Issuance of Legacy Allurion convertible preferred stock for the exercise of warrants	6		6
Issuance of Legacy Allurion convertible preferred stock for the exercise of warrants (in shares)		492
Stock-based compensation expense	401		401
Net Income (Loss)	(21,996)				(21,996)
Ending Balance at Jun. 30, 2023	(71,218)	$ 3	100,768		(171,989)
Ending Balance (in shares) at Jun. 30, 2023		27,126,904
Beginning Balance at Dec. 31, 2023	(70,487)	$ 5	143,007	$ (700)	(212,799)
Beginning Balance (in shares) at Dec. 31, 2023		47,688,096
Exercise of stock options	9		9
Exercise of stock options, (in shares)		4,646
Issuance of common stock for the exercise of Public Warrants (in shares)		142
Issuance of common stock from equity line financing	378		378
Issuance of common stock from equity line financing (in shares)		143,234
Issuance of common stock in connection with vesting of RSU awards (in shares)		62,619
Stock-based compensation expense	552		552
Other comprehensive loss	(2,200)			(2,200)
Net Income (Loss)	5,586				5,586
Ending Balance at Mar. 31, 2024	(66,162)	$ 5	143,946	(2,900)	(207,213)
Ending Balance (in shares) at Mar. 31, 2024		47,898,737
Beginning Balance at Dec. 31, 2023	(70,487)	$ 5	143,007	(700)	(212,799)
Beginning Balance (in shares) at Dec. 31, 2023		47,688,096
Net Income (Loss)	3,424
Ending Balance at Jun. 30, 2024	(70,582)	$ 5	144,768	(5,980)	(209,375)
Ending Balance (in shares) at Jun. 30, 2024		47,972,989
Beginning Balance at Mar. 31, 2024	(66,162)	$ 5	143,946	(2,900)	(207,213)
Beginning Balance (in shares) at Mar. 31, 2024		47,898,737
Exercise of stock options	16		16
Exercise of stock options, (in shares)		11,491
Issuance of common stock for the exercise of Public Warrants	1		1
Issuance of common stock for the exercise of Public Warrants (in shares)		142
Issuance of common stock in connection with vesting of RSU awards (in shares)		62,619
Stock-based compensation expense	805		805
Other comprehensive loss	(3,080)			(3,080)
Net Income (Loss)	(2,162)				(2,162)
Ending Balance at Jun. 30, 2024	$ (70,582)	$ 5	$ 144,768	$ (5,980)	$ (209,375)
Ending Balance (in shares) at Jun. 30, 2024		47,972,989